There's Fungus Among Us. But Where Exactly?
Now, new research suggests that more of these critical hot spots could be hiding beneath our feet — undocumented and largely unprotected.
On Wednesday, an international team of scientists unveiled a global underground atlas, mapping the biodiversity of organisms known as mycorrhizal fungi. The fungi, which live in and on plant roots, form vast underground networks and perform critical ecosystem services, transporting nutrients to plants, storing carbon, bolstering soil health and helping crops survive environmental shocks and stresses.
Using machine learning models, the scientists predicted that rich reservoirs of these fungi lie hidden in some unexpected places, including the Alaskan tundra and Mediterranean woodlands and scrublands. The dense Amazonian jungle did not stand out as a fungal biodiversity hot spot, but the neighboring savanna, the Brazilian Cerrado, did.
'The Amazon of the underground is not actually in the Amazon rainforest,' said Michael Van Nuland, the lead data scientist at the Society for the Protection of Underground Networks, a research organization that led the mapping effort. 'These patterns of diversity that we're seeing are unique.'
Alarmingly, they found, relatively few of these critical hot spots are in ecologically protected areas.
Want all of The Times? Subscribe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 hours ago
- Yahoo
Rapid Expansion and Innovation Drive $36 Billion Global Point-of-Care Diagnostics Market, Says New Kalorama Report
ARLINGTON, Va., July 29, 2025 /PRNewswire/ -- A new report from Kalorama Information reveals that the global point-of-care (POC) diagnostics market surged past $36 billion in 2024, with projections pointing to continued growth through 2029. The twelfth edition of Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition highlights how decentralization of healthcare, rapid innovation, and consumer-driven demand are reshaping how and where diagnostic tests are performed—from traditional clinical settings to homes, workplaces, and remote environments. "POC testing is no longer a fringe segment—it is a central pillar of modern diagnostics," said Melissa Elder, Senior Analyst at Kalorama Information. "We see industry leaders like Abbott, Dexcom, Roche, Danaher, and Exact Sciences innovating aggressively, with POC solutions spanning blood gases, infectious disease, colon cancer, glucose monitoring, and more." The report identifies major growth opportunities in oncology, stroke, dementia, cardiac markers, and glucose management. With transportable and handheld devices becoming more widely available, the reach of point-of-care testing is extending to urgent care centers, disaster relief zones, and at-home monitoring. While the market is recovering from the COVID-19 testing surge of 2020–2022, momentum continues thanks to emerging technologies and the expanding need for fast, accurate, and accessible diagnostics. Trends Shaping the Future of POC Diagnostics: Wearables and mobile health tools Telehealth integration CRISPR and microfluidics innovation Multiplexed and AI-enabled testing Regulatory challenges and LDT policy changes The rise of non-invasive and consumer-friendly testing China's expanding role in the global POC landscape Key Takeaways from the Report: $36 Billion in Global Revenues (2024): Driven by demand in physician offices, clinics, and mobile care, with steady mid-single-digit CAGR expected through 2029. Top Growth Areas: Oncology, stroke, dementia, cardiac, and continuous glucose monitoring (CGM). Next-Gen Tech Impact: Innovations in CRISPR diagnostics, biosensors, and AI are transforming point-of-care capabilities. POC Molecular Diagnostics Rise: Originally accelerated by COVID-19, molecular POC testing is gaining relevance in emergency care and field screening worldwide. Consumer-Led Prevention: Wearables and Bluetooth-enabled tools support proactive health monitoring. Market Leaders and Competitive Landscape "Abbott leads the global market with over 25% share due to its expansive POC portfolio," said Elder. "Dexcom and Roche are advancing CGM and coagulation testing, while Exact Sciences is driving growth in colon cancer diagnostics. Danaher's Beckman Coulter continues to deliver in blood, cancer, and infectious disease testing." An Essential Industry Resource The report is a vital tool for product developers, investors, and healthcare strategists navigating market trends and emerging opportunities. It answers critical questions such as: Where is POC testing growing fastest? What technologies are reshaping diagnostic accessibility? How are regulations and reimbursement shaping adoption? What are the most promising new test types and applications? What's Inside: Global market forecasts through 2029 In-depth segmentation across 10+ test categories Venue analysis (hospital, clinic, retail, home) Competitive landscape profiles and regulatory updates Access the Report Worldwide Market for Point-of-Care Diagnostic Tests, 12th Edition is now available: To request the report or schedule a briefing:Sheri Davie – Kalorama Information Sales For media inquiries:Richa Singh – VP, Strategic & Insights About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a leading publisher of independent market research in medical diagnostics, biotechnology, and life sciences. Our reports help global healthcare organizations, investors, and innovators make informed decisions with confidence. View original content to download multimedia: SOURCE Kalorama Information
Medscape
17 hours ago
- Medscape
Alcohol and Pancreatic Cancer: New Evidence About Risk
Does drinking alcohol increase the risk for pancreatic cancer? Researchers have long suspected it does, but the evidence has remained inconsistent. Now, a global study of more than two million people is firming up the case that a link exists. The study, which pooled data from 30 prospective cohorts, found that daily alcohol intake was associated with a 'modest' increased risk for pancreatic cancer in both women and men, regardless of smoking status. However, the extent of the risk depended somewhat on how the researchers modeled alcohol intake. One model, which mapped continuous increases in alcohol consumption, suggested there is no safe dose of alcohol — any amount can increase the risk for pancreatic cancer, though only by 3% for every additional 10 g of alcohol per day or about two thirds of a standard drink. The other model, which compared risk by alcohol volume categories, found that the risk does not become significant until a certain alcohol threshold — about two to three drinks per day for men and one to two for women. Still, overall, 'our findings provide new evidence that pancreatic cancer may be another cancer type associated with alcohol consumption, a connection that has been underestimated until now,' the study's senior author Pietro Ferrari, PhD, head of the Nutrition and Metabolism Branch at International Agency for Research on Cancer, said in a statement. The co-author Jeanine Genkinger, PhD, MHS, had a stronger take on the findings. 'I think this shows that alcohol use is a robust risk factor for pancreatic cancer,' said Genkinger, associate professor, epidemiology, Columbia University Mailman School of Public Health, New York City, noting that even more moderate drinking levels— no more than one drink for women and two for men — might be enough to boost pancreatic cancer risk. How Much of a Risk? The latest data, published in PLoS Medicine, come at a time of increased attention to the alcohol-cancer link. Earlier this year, then-US Surgeon General Vivek Murthy, MD, issued an advisory calling for cancer warnings to be added to alcohol labels. Major cancer organizations have determined alcohol to be an established risk factor for seven cancer types : those of the oral cavity, larynx, pharynx, esophagus, liver, breast, and colon/rectum. Despite the strong suspicion that drinking alcohol also contributes to pancreatic cancer risk, this aggressive cancer has not yet made the official list. The major reason is that the evidence surrounding an alcohol-pancreatic cancer link has been deemed 'inconsistent,' 'suggestive,' and 'inconclusive' by expert panels. Studies have been hampered by difficulties separating alcohol use from smoking — a known risk factor for pancreatic cancer — as well as varying findings by alcohol type and geographic location. In addition, certain studies highlighting a link have indicated that any association between alcohol and pancreatic cancer is driven only by more extreme drinking habits — more than four drinks a day, and sometimes as high as nine drinks. The latest analysis, Genkinger said, helps clarify uncertainty surrounding the alcohol-pancreatic cancer link, which is especially important for 'a disease where we don't have that many modifiable risk factors.' The findings are based on cohorts spanning four continents, all part of the Pooling Project of Prospective Studies of Diet and Cancer. Just under 2.5 million cancer-free participants were recruited between 1980 and 2013 (median age, 57 years), of whom 70% were alcohol drinkers, 47% were never-smokers, and 64% were alcohol drinkers and never smokers. Most study participants were from North America (60%), followed by Europe or Australia (32%) and Asia (8%). Alcohol intake was modeled in two ways: continuously for every 10 g/d increase and by volume threshold, using 0.1 to < 5 g/d as the reference for nondrinkers. For context, in the US, the amount of alcohol in a standard drink is defined as 14 g of pure alcohol — equivalent to a 12-ounce can of regular beer, a 5-ounce glass of wine, or a 1.5-ounce shot glass of distilled spirits. Over a median of 16 years, the researchers observed 10,067 incidents of pancreatic cancers. In the continuous model, the risk for pancreatic cancer rose by 3% for every additional 10 g of alcohol consumed per day (hazard ratio [HR],1.03; 95% CI, 1.02-1.04). This association remained consistent and significant among women and men (HR, 1.03 for both), current smokers (HR, 1.03), former smokers (HR, 1.02), and never-smokers (HR, 1.03), and across cohorts from Australia, Europe, and North America (HR, 1.03 for all), though not Asia (HR, 1.00). The research team also found evidence that the type of alcohol mattered: Alcohol from beer and liquor/spirits was associated with a significantly increased risk for pancreatic cancer (HR, 1.02 and 1.04, respectively) but alcohol from wine was not (HR, 1.00). This finding is in line with some previous studies suggesting that wine may have a different relationship with cancer risk compared with other alcoholic beverages. But Genkinger pointed out, this finding could 'reflect the ways in which people tend to drink different types of alcohol.' Wine, she noted, is often part of a meal, and people who favor wine may be less likely to binge drink than those who typically choose other types of alcohol. This study, however, did not survey participants about specific drinking patterns, including binge-drinking. In the threshold model, however, the increased risk only became significant once alcohol intake reached a certain level. For women, drinking one to two standard drinks per day raised their risk for pancreatic cancer by 12% compared with little to no drinking. For men, the threshold was a little higher: Consuming two to four drinks a day was associated with a 15% increase in risk, whereas drinking more than that was tied to a 36% greater risk. Overall, this research contributes to the growing body of evidence that pancreatic cancer should be added to the official alcohol-cancer risk list, according to Alison Klein, PhD, MHS, professor of oncology, pathology, and epidemiology, at Johns Hopkins School of Medicine, Baltimore, who was not involved in the research. Having the Conversation The recent Surgeon General's advisory encouraged clinicians to inform their patients that drinking is a cancer risk factor — something unknown to most Americans, according to recent survey findings. 'I think this study is a good reminder to all of us to talk to our patients about their alcohol use,' said Edward Thomas Lewis III, MD, an addiction psychiatrist and clinical assistant professor at the Medical University of South Carolina, Charleston, South Carolina. Providers can take opportunities for those discussions during routine care, such as when prescribing a medication that can interact with alcohol or when a patient's health condition, such as high blood pressure or heart disease, can be exacerbated by drinking. 'I think these are opportunities to really remind people about moderation,' Lewis said, 'and to talk about some of the individual risk factors that may cause someone to make changes related to their drinking.' It's also possible that drinking might interact with certain genetic variants to modify pancreatic cancer risk — an avenue Klein and colleagues are exploring. What's challenging, Lewis said, is advising patients on what level of drinking is 'Okay,' given that even lower levels of alcohol consumption — around one to two drinks per day — may carry some risk. 'There is no zero-risk alcohol use,' Lewis said. But, he added, people do not necessarily have to abstain to see benefits, either. 'So it may be that a patient, at the end of the day, is able to reduce their alcohol consumption by two or three standard drinks over a given week. That still has a positive net effect,' he said. Another challenge is patients often don't know what a 'standard drink' looks like and can underestimate how much they drink. Showing patients visual examples — such as these— can be an eye-opener, Lewis said. Given the associations between drinking alcohol and many health outcomes, Genkinger said, it's important for clinicians to discuss alcohol use, just as they would discuss physical activity and healthy body weight. 'These are all lifestyle factors that have an impact on numerous disease outcomes, not only pancreatic cancer,' she said.
Gizmodo
18 hours ago
- Gizmodo
This Ancient Roman Artifact Is Also a 453 Million-Year-Old Fossil
Despite how Ross' paleontology career is treated by his companions in Friends, there's something special about finding the remains of creatures that lived millions if not billions of years before us. In fact, humanity's interest in paleontology isn't a modern development. Ancient Romans were just as fascinated by fossils. According to the ancient Roman historian Suetonius, Emperor Augustus established the first known paleontological museum at his villa on the island of Capri, where he showcased the bones of ancient 'giants' and 'monsters.' While paleontologists have yet to uncover such fantastical remains, a study published Thursday in the journal Science describes something that, in my opinion, is even more special—an ancient Roman amulet crafted from the fossil of a critter that lived between 453 and 460 million years ago. The researchers claim that the artifact 'represents the first documented trilobite in the Roman world and the earliest known reference to this fossil group—and the intentional manipulation of a trilobite specimen—in all of classical antiquity,' they wrote in the study. Trilobites are a group of marine arthropods that existed between 521 and 251 million years ago. It's also the 'third trilobite in the global archaeological record to have been collected and used by people over a thousand years ago,' they added. The rare artifact came to light in a Roman settlement in northwestern Spain called A Cibdá of Armea that existed from the first to the third century CE. The researchers suggest that the fossil itself originated in shale outcrops over 267 miles (430 kilometers) away from the Roman settlement. The trilobite likely reached the settlement via trade or as the property of someone from central Lusitania (a Roman province in Spain) moving to the region. Either way, someone clearly altered the fossil. 'The Armea trilobite fragment unquestionably shows evidence of anthropic work, particularly on the underside and left side of the piece,' the researchers explained. 'These marks do not affect the upper surface, which displays the characteristic articulated segments of a trilobite's dorsal exoskeleton. It seems clear that the person who modified the stone intended to leave that natural surface untouched, while simultaneously adapting the fossil to its new function.' According to the study, the modified fossil could have functioned as a game token, a part of a necklace or bracelet, a banded pendant on a metallic mount, or simply an object people carried in their bag or pocket. Regardless of how the trilobite was fashioned, it was likely kept for supernatural, propitiatory, or medicinal purposes and abandoned between the first and third centuries CE. 'It is plausible to consider that the Armea trilobite may have been perceived to hold magical and protective powers for its wearer, as is the case with fossils or even trilobites in other well-known archaeological contexts,' the researchers wrote. Coincidentally, archaeologists found the trilobite next to a bronze coin of Augustus. The discovery is a testament to the fact that humanity's curiosity for that which came before us is a universal trait that transcends cultures, borders, and even time itself. It stands as a reassuring reminder, especially in times like these—when the only thing everyone seems to agree on is our many differences.
